azd9574
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 24, 2022 (NCT05417594)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07181161 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2025 | AstraZeneca, Parexel |
| NCT05417594 | Phase 1/Phase 2 (Phase 2) | Jun 24, 2022 | AstraZeneca |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 2 | 1 | 2022 |
| Parexel | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1